Merck & Company (MRK) 53.95 $MRK
Here's Why Advaxis' Stock Gained 11% in October
George Budwell, The Motley Fool - Motley Fool - Tue Nov 17, 9:59AM CST
What : Advaxis , a clinical-stage cancer immunotherapy company, saw its shares gain over 11% in October, according to data provided by S&P Capital IQ . Even so, the company didn't exactly have a good month. Advaxis kicked off the month by ...
ADXS: 12.14 (-0.24), MRK: 53.94 (+0.24), AZN: 33.39 (+0.61)
New Studies Investigating the Use of KEYTRUDA(R) (pembrolizumab) Across Solid and Hematological Cancers to Be Presented at Upcoming Congresses
Business Wire - Tue Nov 17, 7:00AM CST
--New Findings of KEYTRUDA in Novel Combinations with Other Immunotherapies in Advanced Melanoma
MRK: 53.94 (+0.24)
World Flow Cytometry Market Opportunities and Forecasts 2014-2022
M2 - Tue Nov 17, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/6sgk45/_world_flow) has announced the addition of the " World Flow Cytometry - Market Opportunities and Forecast, 2014 - 2022" report to their offering. The world flow cytometry market is estimated to reach $7.0 billion by 2022, registering a CAGR of 16.0% over the forecast period Flow cytometry is a biophysical, laser based analytical technology that measures and analyses several physical characteristics of cells or particles suspended in a fluid, when passed through a laser beam. Flow cytometry has various advantages over traditional analytical methods such as ELISA, which include its ability to deliver precise and accurate results and lesser time consumption at about same prices. The flow cytometry technology is widely used in the various fields of academic and clinical research, and diagnosis of diseases such as cancer, HIV and hematological malignancies. Rising count of patients suffering from HIV and cancer and increasing use of flow cytometry in hospitals and diagnostic centers, has created an impending need of flow cytometry in the effective diagnosis and monitoring of diseases. World flow cytometry market is set to grow at a remarkable pace in the coming years, attributed to technological advancements and high adoption in various research and diagnostic applications. In addition, the advent of flow cytometry technology in novel research applications such as cytogenomics, proteomics and marine biology would further supplement the market growth. Further, rising incidence rates of diseases such as cancer and HIV are likely to boost the adoption of flow cytometry technology across diagnostic applications. On the other hand, factors such as high cost associated with instruments and reagents, lack of awareness among potential end users and the limited availability of technical expertise are likely to impede the market growth. The preference of flow cytometry in drug discovery & development and diagnostics is expected to provide numerous growth opportunities. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 World Flow Cytometry Market, By Component, 2014-2022 Chapter 5 World Flow Cytometry Market, By Technology, 2014-2022 Chapter 6 World Flow Cytometry Market, By Application, 2014-2022 Chapter 7 World Flow Cytometry Market, By End User, 2014-2022 Chapter 8 World Flow Cytometry Market, By Geography, 2014-2022 Chapter 9 Company Profiles - Affymetrix Inc. - Becton - Bio-Rad Laboratories - Dako (Agilent Technologies) - Danaher Corporation (Beckman Coulter) - Dickinson and Co. - Luminex Corporation - Merck Millipore - Miltenyi Biotec GmbH. - Sysmex Corporation - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/6s...world_flow
A: 38.31 (+0.98), MRK: 53.94 (+0.24), LMNX: 20.79 (+0.05), DHR: 95.70 (+0.55), AFFX: 9.01 (+0.09)
AbbVie Reports Encouraging Data on HCV Drug Viekira Pak
Zacks Equity Research - Zacks Investment Research - Mon Nov 16, 4:27PM CST
AbbVie Inc. (ABBV) announced encouraging new data from its ongoing phase IIIb TOPAZ-II study evaluating hepatitis C virus infection drug, Viekira Pak.
JNJ: 101.64 (+0.42), GILD: 104.68 (+0.87), MRK: 53.94 (+0.24), ABBV: 60.77 (+0.76)
The Deal Announces Winners Of The Eighth Annual Most Admired Corporate Dealmakers Awards
PR Newswire - Mon Nov 16, 12:27PM CST
Today The Deal, a business unit of TheStreet (NASDAQ: TST), announced the winners of the eighth annual Most Admired Corporate Dealmakers (MACD) Awards, which recognize the best corporate dealmaking teams at acquisitive, large-cap U.S. companies in ten industry groups. Each year, winners are selected from major S&P industry groups and through a survey of The Deal's audience. Voters determine which candidate in each industry excelled in overall M&A strategy based on the criteria of strategy, choice of targets, deal execution and team skill.
TST: 1.70 (+0.07), MRK: 53.94 (+0.24)
3 High-Yield Dividend Stocks You Don't Have to Babysit
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Nov 16, 8:19AM CST
Image by Markgraf-Ave via Pixabay With the S&P 500 once again in negative territory for the year, companies of all sizes have seen their share prices decline. When a stock that pays a strong dividend goes down, it has the happy effect of...
PFE: 33.25 (+0.09), MRK: 53.94 (+0.24), ABBV: 60.77 (+0.76)
Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting(R)
Business Wire - Mon Nov 16, 7:30AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the initial phase (Part A) of the company's C-CREST 1 and 2 Phase 2 clinical development program evaluating two investigational all-oral, triple-combination treatment regimens - a regimen of grazoprevir(1), MK-3682(2) andelbasvir(3); and a regimen of grazoprevir, MK-3682 and MK-8408(4) - in treatment-naive patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 2 or 3 infection. These data will be presented today during a late-breaking abstract session at The Liver Meeting(R) (Abstract #LB-15). Based on the results of this initial trial, Merck has initiated further study of grazoprevir (100mg), MK-3682 (450mg) and MK-8408 (60mg) in the second phase (Part
of the C-CREST Phase 2 clinical development program.
MRK: 53.94 (+0.24)
Survey: Shopping Trumps Health during the Holiday Season
PR Newswire - Mon Nov 16, 7:07AM CST
Merck Manuals (called MSD Manuals outside of the United States and Canada, and together, The Manuals), one of the world's most widely-used medical resources since 1899, today released the results of a survey revealing that among those who have been sick during the holiday season, more than half (51 percent) have gone shopping while ill and nearly 2 in 3 (65 percent) confessed to going to work or school while sick.
MRK: 53.94 (+0.24)
Broadridge Names Julie Taylor as Chief Human Resources Officer, Laura Matlin as Chief Governance Officer
PR Newswire - Mon Nov 16, 7:00AM CST
Broadridge Financial Solutions, Inc. (NYSE: BR) today announced that Julie Taylor has been appointed chief human resources officer (CHRO) and member of Broadridge's executive committee. Taylor succeeds Laura Matlin, who has served as acting CHRO for the past year. Matlin will return to her legal duties as deputy general counsel and will assume the newly-created role of chief governance officer, also serving on the company's executive committee.
BR: 55.21 (+0.05), MRK: 53.94 (+0.24)
Global Anti-Inflammatory Therapeutics Market 2014-2020 by Indication, Drug Class & Geography
PR Newswire Europe - Mon Nov 16, 6:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/8rkdpz/world [http://www.researchandmarkets.com/research/8rkdpz/world]) has announced the addition of the "World Anti-Inflammatory Therapeutics Market - Opportunities and Forecasts, 2014 - 2020" [http://www.researchandmarkets.com/research/8rkdpz/world] report to their offering.
JNJ: 101.64 (+0.42), PFE: 33.25 (+0.09), MRK: 53.94 (+0.24), AZN: 33.39 (+0.61), AMGN: 158.89 (+4.39), ABBV: 60.77 (+0.76), GSK: 40.70 (+0.47), NVS: 87.81 (+0.76)
World Anti-Inflammatory Therapeutics Market Opportunities and Forecasts, 2020 - Anti-inflammatory Therapeutics Market is Expected to Reach $106.1 Billion
M2 - Mon Nov 16, 2:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/qwnb7n/world) has announced the addition of the "World Anti-Inflammatory Therapeutics Market - Opportunities and Forecasts, 2014 - 2020" report to their offering. The global anti-inflammatory therapeutics market is expected to grow at a CAGR of 5.9% over the forecast period, owing to the emergence of anti-inflammatory biologics that are more targeted, effective and with lesser side effects as compared to conventional drugs. In addition, they are also difficult to imitate due to their complex molecular structure and origin. The global anti-inflammatory market has been driven by factors such as increasing autoimmune and respiratory conditions, new drugs in pipeline and increasing adoption of anti-inflammatory drugs. Moreover, increasing awareness of anti-inflammatory therapeutics and attractive government initiatives in the Asia-Pacific and LAMEA region are expected to drive the market during the analysis period. Factors, such as side effects of anti-inflammatory drugs and patent expiry issues of blockbuster drugs (such as Remicade), are known to impede the market growth. The global anti-inflammatory therapeutics market is segmented on the basis of indication, drug class and geography. The indications considered in this report include arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel disease and other inflammatory diseases. Among indications, arthritis holds tremendous potential for growth accounting for 38.2% of the global anti-inflammatory therapeutics market. Anti-inflammatory biologics are the most preferred drugs for treatment of arthritis. On the basis of drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Anti-inflammatory biologics holds the largest share among drug classes accounting for 54.8% share of the global anti-inflammatory therapeutics market, and is expected grow rapidly during the forecast period. Key Topics Covered: Chapter: 1 Introduction Chapter: 2 Executive Summary Chapter: 3 Market Overview Chapter: 4 Global Anti-Inflammatory Therapeutics Market By Indication Chapter: 5 Global Anti-Inflammatory Therapeutics Market By Drug Class Chapter: 6 Global Anti-Inflammatory Therapeutics Market By Geography Chapter: 7 Company Profiles - AbbVie Inc - Amgen Inc. - AstraZeneca PLC. - Eli Lily and Company - GlaxoSmithKline plc - Hoffmann-La Roche AG - Johnson & Johnson - Merck & Co. - Novartis AG - Pfizer Inc For more information visit http://www.researchandmarkets.com/research/qwnb7n/world
JNJ: 101.64 (+0.42), PFE: 33.25 (+0.09), MRK: 53.94 (+0.24), AZN: 33.39 (+0.61), AMGN: 158.89 (+4.39), ABBV: 60.77 (+0.76), GSK: 40.70 (+0.47), NVS: 87.81 (+0.76)
World Biosimilars/Follow-on-Biologics Market - Opportunities and Forecasts 2014-2020
M2 - Mon Nov 16, 2:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/m64n9d/world) has announced the addition of the "World Biosimilars/Follow-on-Biologics Market - Opportunities and Forecasts, 2014 - 2020" report to their offering. Global biosimilars/follow-on-biologics market accounted for an overall revenue of $2,552.0 million in 2014 and it is estimated to generate an approximate revenue of $26,551.3 million by 2020, registering a CAGR of 49.1% from 2015 to 2020. Biosimilars or follow-on-biologics are highly similar versions of reference biologics derived from living organisms such as plants and animals. The development of biosimilars and validation with reference biologics play a significant role in the commercialization of biosimilars. Economic pricing of biosimilars, ease in development and a quick approval process are some key driving factors that drive the growth of this market. Effective and timely formulated regulations facilitate the viability and balance between original and biosimilar products. Moreover, a favorable regulatory environment and the establishment of IPR protections are factors that boost the market growth. The upcoming patent expiration for blockbuster drugs has revolutionized the aspect of commercialization whilst triggering a large scale adoption of biosimilars. Biosimilars industry is facing problems relating to production efficiency and quantity. The lack of economies of scale for small scale manufacturers and absence of regulatory guidelines in lucrative regions such as China, US are hindering the growth of biosimilars market. However, strong government initiatives pertaining to production and approval is a key factor that would eventually reduce the impact of these restraints over the forecast period. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Market By Technology Chapter 5 Global Biosimilars Market By Product Chapter 6 Global Market By Applications Chapter 7 Global Market By Services Chapter 8 Global Biosimilars Market By Geography Chapter 9 Key Products And Recent Activities Chapter 10 Company Profiles - Biocon - Biogen idec Inc. - Celltrion - Genentech (Roche Group) - Hospira - LG Life Sciences - Merck Serono (Merck Group) - Novartis (Sandoz) - Synthon Pharmaceuticals - Teva Pharmaceutical Industries Ltd. For more information visit http://www.researchandmarkets.com/research/m64n9d/world
MRK: 53.94 (+0.24), TEVA: 60.31 (+1.50), NVS: 87.81 (+0.76)
Exelixis, Inc. Earnings: Riding the Meteor
Brian Orelli, The Motley Fool - Motley Fool - Sun Nov 15, 5:00PM CST
Exelixis reported earnings on Tuesday, and as usual, the pipeline was much more important for the biotech than its revenue and profit. Exelixis results: The raw numbers Metric Q3 2015 Actuals Q3 2014 Actuals Growth (YOY)...
MRK: 53.94 (+0.24), BMY: 66.02 (+1.00), EXEL: 5.68 (+0.20)
Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting(R)
Business Wire - Sat Nov 14, 6:00PM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir(1) (50mg/100mg) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection. Results from the full analysis set (FAS) (n=402) demonstrate that treatment-naive patients with compensated liver cirrhosis who received elbasvir/grazoprevir with or without RBV for 12 weeks achieved sustained virologic response 12 weeks after the completion of treatment (SVR12, or virologic cure) at rates of 90 percent (28/31) and 98 percent (135/138), respectively. Treatment-experienced patients who received elbasvir/grazoprevir with or without RBV for 12 weeks achieved virologic cure rates of 91 percent (74/81) and 89 percent (48/54), respectively. Treatment-experienced patients who received elbasvir/grazoprevir with or without RBV for 16 or 18 weeks achieved virologic cure rates of 100 percent (49/49) and 94 percent (46/49), respectively. These data will be presented during an oral presentation at The Liver Meeting(R) (Abstract #42).
MRK: 53.94 (+0.24)
Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy
Business Wire - Sat Nov 14, 6:00PM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the company's Phase 3 C-EDGE CO-STAR clinical trial evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir(1) (50mg/100mg) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection who inject drugs and are receiving opioid agonist therapy (OAT). Ninety-five percent (189/198) of patients treated with elbasvir/grazoprevir for 12 weeks in the pre-specified primary efficacy analysis population achieved sustained virologic response 12 weeks after the completion of treatment (SVR12, considered virologic cure). Adherence to treatment was high, with 97 percent of patients taking at least 95 percent of their study medication over the 12 weeks of therapy. These findings will be featured today at the American Association for the Study of Liver Diseases' President's Press Conference at The Liver Meeting(R) and presented in an oral session on Monday, November 16 (Abstract #40).
MRK: 53.94 (+0.24)
Facebook, Apple, Gilead Honchos Lead Insider Deals
at Investor's Business Daily - Fri Nov 13, 5:21PM CST
An early investor in Facebook (FB) continued to sell shares of the social media leader this past week as the stock peaked, while Apple's (AAPL) chief sold another chunk of the iPhone maker's stock, which slumped. Facebook Director Marc Andreessen,...
FSLR: 53.36 (-0.82), SWKS: 77.58 (+2.30), GILD: 104.68 (+0.87), SUNE: 3.38 (-1.18), FB: 105.97 (+1.93), MRK: 53.94 (+0.24), STZ: 138.49 (+3.23), ILMN: 173.30 (+3.19), AAPL: 114.29 (+0.11)
Merck continuing study of cholesterol drug in new class
By LINDA A. JOHNSON - AP - Fri Nov 13, 1:16PM CST
TRENTON, N.J. (AP) — Merck & Co. said Friday that it will continue a huge patient study of an experimental cholesterol medicine, the last one standing in a once-promising class of drugs being developed to prevent heart attacks, after an independent monitoring committee recommended the study continue.
PFE: 33.25 (+0.09), MRK: 53.94 (+0.24), AMGN: 158.89 (+4.39), LLY: 81.72 (+0.49), REGN: 571.60 (+13.22)
Gilead's (GILD) HCV Drug Harvoni's Label Expanded in U.S.
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 1:15PM CST
Gilead Sciences, Inc. (GILD) announced a label expansion for its hepatitis C virus infection drug, Harvoni, in the U.S.
GILD: 104.68 (+0.87), MRK: 53.94 (+0.24), ABBV: 60.77 (+0.76), BXLT: 34.14 (-0.34)
Immune Design Posts Narrower-Than-Expected Loss for Q3
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 9:35AM CST
Immune Design's (IMDZ) Q3 loss was narrower than expected.
IMDZ: 18.60 (-0.15), MRK: 53.94 (+0.24), CORT: 4.79 (unch), SNY: 43.79 (+0.67)
Hepatitis C Treatment in 2016: Will Gilead Sciences or AbbVie Win?
Motley Fool Staff - Motley Fool - Fri Nov 13, 7:41AM CST
Gilead Sciences is a favorite healthcare stock for numerous Fools, and it's no surprise why. The recent stumble of AbbVie in its hepatitis C efforts has boosted the share price of Gilead, which has two key treatments that fight the illness. ...
GILD: 104.68 (+0.87), MRK: 53.94 (+0.24), ABBV: 60.77 (+0.76), BMY: 66.02 (+1.00)
Here's Why Advaxis' Stock Gained 11% in October
George Budwell, The Motley Fool - Motley Fool - Tue Nov 17, 9:59AM CST
What : Advaxis , a clinical-stage cancer immunotherapy company, saw its shares gain over 11% in October, according to data provided by S&P Capital IQ . Even so, the company didn't exactly have a good month. Advaxis kicked off the month by ...
ADXS: 12.14 (-0.24), MRK: 53.94 (+0.24), AZN: 33.39 (+0.61)
New Studies Investigating the Use of KEYTRUDA(R) (pembrolizumab) Across Solid and Hematological Cancers to Be Presented at Upcoming Congresses
Business Wire - Tue Nov 17, 7:00AM CST
--New Findings of KEYTRUDA in Novel Combinations with Other Immunotherapies in Advanced Melanoma
MRK: 53.94 (+0.24)
World Flow Cytometry Market Opportunities and Forecasts 2014-2022
M2 - Tue Nov 17, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/6sgk45/_world_flow) has announced the addition of the " World Flow Cytometry - Market Opportunities and Forecast, 2014 - 2022" report to their offering. The world flow cytometry market is estimated to reach $7.0 billion by 2022, registering a CAGR of 16.0% over the forecast period Flow cytometry is a biophysical, laser based analytical technology that measures and analyses several physical characteristics of cells or particles suspended in a fluid, when passed through a laser beam. Flow cytometry has various advantages over traditional analytical methods such as ELISA, which include its ability to deliver precise and accurate results and lesser time consumption at about same prices. The flow cytometry technology is widely used in the various fields of academic and clinical research, and diagnosis of diseases such as cancer, HIV and hematological malignancies. Rising count of patients suffering from HIV and cancer and increasing use of flow cytometry in hospitals and diagnostic centers, has created an impending need of flow cytometry in the effective diagnosis and monitoring of diseases. World flow cytometry market is set to grow at a remarkable pace in the coming years, attributed to technological advancements and high adoption in various research and diagnostic applications. In addition, the advent of flow cytometry technology in novel research applications such as cytogenomics, proteomics and marine biology would further supplement the market growth. Further, rising incidence rates of diseases such as cancer and HIV are likely to boost the adoption of flow cytometry technology across diagnostic applications. On the other hand, factors such as high cost associated with instruments and reagents, lack of awareness among potential end users and the limited availability of technical expertise are likely to impede the market growth. The preference of flow cytometry in drug discovery & development and diagnostics is expected to provide numerous growth opportunities. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 World Flow Cytometry Market, By Component, 2014-2022 Chapter 5 World Flow Cytometry Market, By Technology, 2014-2022 Chapter 6 World Flow Cytometry Market, By Application, 2014-2022 Chapter 7 World Flow Cytometry Market, By End User, 2014-2022 Chapter 8 World Flow Cytometry Market, By Geography, 2014-2022 Chapter 9 Company Profiles - Affymetrix Inc. - Becton - Bio-Rad Laboratories - Dako (Agilent Technologies) - Danaher Corporation (Beckman Coulter) - Dickinson and Co. - Luminex Corporation - Merck Millipore - Miltenyi Biotec GmbH. - Sysmex Corporation - Thermo Fisher Scientific For more information visit http://www.researchandmarkets.com/research/6s...world_flow
A: 38.31 (+0.98), MRK: 53.94 (+0.24), LMNX: 20.79 (+0.05), DHR: 95.70 (+0.55), AFFX: 9.01 (+0.09)
AbbVie Reports Encouraging Data on HCV Drug Viekira Pak
Zacks Equity Research - Zacks Investment Research - Mon Nov 16, 4:27PM CST
AbbVie Inc. (ABBV) announced encouraging new data from its ongoing phase IIIb TOPAZ-II study evaluating hepatitis C virus infection drug, Viekira Pak.
JNJ: 101.64 (+0.42), GILD: 104.68 (+0.87), MRK: 53.94 (+0.24), ABBV: 60.77 (+0.76)
The Deal Announces Winners Of The Eighth Annual Most Admired Corporate Dealmakers Awards
PR Newswire - Mon Nov 16, 12:27PM CST
Today The Deal, a business unit of TheStreet (NASDAQ: TST), announced the winners of the eighth annual Most Admired Corporate Dealmakers (MACD) Awards, which recognize the best corporate dealmaking teams at acquisitive, large-cap U.S. companies in ten industry groups. Each year, winners are selected from major S&P industry groups and through a survey of The Deal's audience. Voters determine which candidate in each industry excelled in overall M&A strategy based on the criteria of strategy, choice of targets, deal execution and team skill.
TST: 1.70 (+0.07), MRK: 53.94 (+0.24)
3 High-Yield Dividend Stocks You Don't Have to Babysit
Brian Feroldi, Todd Campbell, and George Budwell, The Motley Fool - Motley Fool - Mon Nov 16, 8:19AM CST
Image by Markgraf-Ave via Pixabay With the S&P 500 once again in negative territory for the year, companies of all sizes have seen their share prices decline. When a stock that pays a strong dividend goes down, it has the happy effect of...
PFE: 33.25 (+0.09), MRK: 53.94 (+0.24), ABBV: 60.77 (+0.76)
Merck Announces Presentation of Results from Two Phase 2 Studies of Investigational Triple-Combination Chronic Hepatitis C Therapy at The Liver Meeting(R)
Business Wire - Mon Nov 16, 7:30AM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the initial phase (Part A) of the company's C-CREST 1 and 2 Phase 2 clinical development program evaluating two investigational all-oral, triple-combination treatment regimens - a regimen of grazoprevir(1), MK-3682(2) andelbasvir(3); and a regimen of grazoprevir, MK-3682 and MK-8408(4) - in treatment-naive patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 2 or 3 infection. These data will be presented today during a late-breaking abstract session at The Liver Meeting(R) (Abstract #LB-15). Based on the results of this initial trial, Merck has initiated further study of grazoprevir (100mg), MK-3682 (450mg) and MK-8408 (60mg) in the second phase (Part
of the C-CREST Phase 2 clinical development program. MRK: 53.94 (+0.24)
Survey: Shopping Trumps Health during the Holiday Season
PR Newswire - Mon Nov 16, 7:07AM CST
Merck Manuals (called MSD Manuals outside of the United States and Canada, and together, The Manuals), one of the world's most widely-used medical resources since 1899, today released the results of a survey revealing that among those who have been sick during the holiday season, more than half (51 percent) have gone shopping while ill and nearly 2 in 3 (65 percent) confessed to going to work or school while sick.
MRK: 53.94 (+0.24)
Broadridge Names Julie Taylor as Chief Human Resources Officer, Laura Matlin as Chief Governance Officer
PR Newswire - Mon Nov 16, 7:00AM CST
Broadridge Financial Solutions, Inc. (NYSE: BR) today announced that Julie Taylor has been appointed chief human resources officer (CHRO) and member of Broadridge's executive committee. Taylor succeeds Laura Matlin, who has served as acting CHRO for the past year. Matlin will return to her legal duties as deputy general counsel and will assume the newly-created role of chief governance officer, also serving on the company's executive committee.
BR: 55.21 (+0.05), MRK: 53.94 (+0.24)
Global Anti-Inflammatory Therapeutics Market 2014-2020 by Indication, Drug Class & Geography
PR Newswire Europe - Mon Nov 16, 6:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/8rkdpz/world [http://www.researchandmarkets.com/research/8rkdpz/world]) has announced the addition of the "World Anti-Inflammatory Therapeutics Market - Opportunities and Forecasts, 2014 - 2020" [http://www.researchandmarkets.com/research/8rkdpz/world] report to their offering.
JNJ: 101.64 (+0.42), PFE: 33.25 (+0.09), MRK: 53.94 (+0.24), AZN: 33.39 (+0.61), AMGN: 158.89 (+4.39), ABBV: 60.77 (+0.76), GSK: 40.70 (+0.47), NVS: 87.81 (+0.76)
World Anti-Inflammatory Therapeutics Market Opportunities and Forecasts, 2020 - Anti-inflammatory Therapeutics Market is Expected to Reach $106.1 Billion
M2 - Mon Nov 16, 2:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/qwnb7n/world) has announced the addition of the "World Anti-Inflammatory Therapeutics Market - Opportunities and Forecasts, 2014 - 2020" report to their offering. The global anti-inflammatory therapeutics market is expected to grow at a CAGR of 5.9% over the forecast period, owing to the emergence of anti-inflammatory biologics that are more targeted, effective and with lesser side effects as compared to conventional drugs. In addition, they are also difficult to imitate due to their complex molecular structure and origin. The global anti-inflammatory market has been driven by factors such as increasing autoimmune and respiratory conditions, new drugs in pipeline and increasing adoption of anti-inflammatory drugs. Moreover, increasing awareness of anti-inflammatory therapeutics and attractive government initiatives in the Asia-Pacific and LAMEA region are expected to drive the market during the analysis period. Factors, such as side effects of anti-inflammatory drugs and patent expiry issues of blockbuster drugs (such as Remicade), are known to impede the market growth. The global anti-inflammatory therapeutics market is segmented on the basis of indication, drug class and geography. The indications considered in this report include arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel disease and other inflammatory diseases. Among indications, arthritis holds tremendous potential for growth accounting for 38.2% of the global anti-inflammatory therapeutics market. Anti-inflammatory biologics are the most preferred drugs for treatment of arthritis. On the basis of drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Anti-inflammatory biologics holds the largest share among drug classes accounting for 54.8% share of the global anti-inflammatory therapeutics market, and is expected grow rapidly during the forecast period. Key Topics Covered: Chapter: 1 Introduction Chapter: 2 Executive Summary Chapter: 3 Market Overview Chapter: 4 Global Anti-Inflammatory Therapeutics Market By Indication Chapter: 5 Global Anti-Inflammatory Therapeutics Market By Drug Class Chapter: 6 Global Anti-Inflammatory Therapeutics Market By Geography Chapter: 7 Company Profiles - AbbVie Inc - Amgen Inc. - AstraZeneca PLC. - Eli Lily and Company - GlaxoSmithKline plc - Hoffmann-La Roche AG - Johnson & Johnson - Merck & Co. - Novartis AG - Pfizer Inc For more information visit http://www.researchandmarkets.com/research/qwnb7n/world
JNJ: 101.64 (+0.42), PFE: 33.25 (+0.09), MRK: 53.94 (+0.24), AZN: 33.39 (+0.61), AMGN: 158.89 (+4.39), ABBV: 60.77 (+0.76), GSK: 40.70 (+0.47), NVS: 87.81 (+0.76)
World Biosimilars/Follow-on-Biologics Market - Opportunities and Forecasts 2014-2020
M2 - Mon Nov 16, 2:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/m64n9d/world) has announced the addition of the "World Biosimilars/Follow-on-Biologics Market - Opportunities and Forecasts, 2014 - 2020" report to their offering. Global biosimilars/follow-on-biologics market accounted for an overall revenue of $2,552.0 million in 2014 and it is estimated to generate an approximate revenue of $26,551.3 million by 2020, registering a CAGR of 49.1% from 2015 to 2020. Biosimilars or follow-on-biologics are highly similar versions of reference biologics derived from living organisms such as plants and animals. The development of biosimilars and validation with reference biologics play a significant role in the commercialization of biosimilars. Economic pricing of biosimilars, ease in development and a quick approval process are some key driving factors that drive the growth of this market. Effective and timely formulated regulations facilitate the viability and balance between original and biosimilar products. Moreover, a favorable regulatory environment and the establishment of IPR protections are factors that boost the market growth. The upcoming patent expiration for blockbuster drugs has revolutionized the aspect of commercialization whilst triggering a large scale adoption of biosimilars. Biosimilars industry is facing problems relating to production efficiency and quantity. The lack of economies of scale for small scale manufacturers and absence of regulatory guidelines in lucrative regions such as China, US are hindering the growth of biosimilars market. However, strong government initiatives pertaining to production and approval is a key factor that would eventually reduce the impact of these restraints over the forecast period. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Market Overview Chapter 4 Global Market By Technology Chapter 5 Global Biosimilars Market By Product Chapter 6 Global Market By Applications Chapter 7 Global Market By Services Chapter 8 Global Biosimilars Market By Geography Chapter 9 Key Products And Recent Activities Chapter 10 Company Profiles - Biocon - Biogen idec Inc. - Celltrion - Genentech (Roche Group) - Hospira - LG Life Sciences - Merck Serono (Merck Group) - Novartis (Sandoz) - Synthon Pharmaceuticals - Teva Pharmaceutical Industries Ltd. For more information visit http://www.researchandmarkets.com/research/m64n9d/world
MRK: 53.94 (+0.24), TEVA: 60.31 (+1.50), NVS: 87.81 (+0.76)
Exelixis, Inc. Earnings: Riding the Meteor
Brian Orelli, The Motley Fool - Motley Fool - Sun Nov 15, 5:00PM CST
Exelixis reported earnings on Tuesday, and as usual, the pipeline was much more important for the biotech than its revenue and profit. Exelixis results: The raw numbers Metric Q3 2015 Actuals Q3 2014 Actuals Growth (YOY)...
MRK: 53.94 (+0.24), BMY: 66.02 (+1.00), EXEL: 5.68 (+0.20)
Merck to Release Findings from Integrated Analysis of Six Phase 2 and 3 Clinical Trials Evaluating Investigational Elbasvir/Grazoprevir in Patients with Chronic Hepatitis C Genotype 1, 4 or 6 Infection and Compensated Cirrhosis at The Liver Meeting(R)
Business Wire - Sat Nov 14, 6:00PM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from an integrated analysis of patients with compensated liver cirrhosis (Child-Pugh class A) from six Phase 2 and 3 clinical trials evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir(1) (50mg/100mg) with or without ribavirin (RBV) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection. Results from the full analysis set (FAS) (n=402) demonstrate that treatment-naive patients with compensated liver cirrhosis who received elbasvir/grazoprevir with or without RBV for 12 weeks achieved sustained virologic response 12 weeks after the completion of treatment (SVR12, or virologic cure) at rates of 90 percent (28/31) and 98 percent (135/138), respectively. Treatment-experienced patients who received elbasvir/grazoprevir with or without RBV for 12 weeks achieved virologic cure rates of 91 percent (74/81) and 89 percent (48/54), respectively. Treatment-experienced patients who received elbasvir/grazoprevir with or without RBV for 16 or 18 weeks achieved virologic cure rates of 100 percent (49/49) and 94 percent (46/49), respectively. These data will be presented during an oral presentation at The Liver Meeting(R) (Abstract #42).
MRK: 53.94 (+0.24)
Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy
Business Wire - Sat Nov 14, 6:00PM CST
Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the company's Phase 3 C-EDGE CO-STAR clinical trial evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir(1) (50mg/100mg) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection who inject drugs and are receiving opioid agonist therapy (OAT). Ninety-five percent (189/198) of patients treated with elbasvir/grazoprevir for 12 weeks in the pre-specified primary efficacy analysis population achieved sustained virologic response 12 weeks after the completion of treatment (SVR12, considered virologic cure). Adherence to treatment was high, with 97 percent of patients taking at least 95 percent of their study medication over the 12 weeks of therapy. These findings will be featured today at the American Association for the Study of Liver Diseases' President's Press Conference at The Liver Meeting(R) and presented in an oral session on Monday, November 16 (Abstract #40).
MRK: 53.94 (+0.24)
Facebook, Apple, Gilead Honchos Lead Insider Deals
at Investor's Business Daily - Fri Nov 13, 5:21PM CST
An early investor in Facebook (FB) continued to sell shares of the social media leader this past week as the stock peaked, while Apple's (AAPL) chief sold another chunk of the iPhone maker's stock, which slumped. Facebook Director Marc Andreessen,...
FSLR: 53.36 (-0.82), SWKS: 77.58 (+2.30), GILD: 104.68 (+0.87), SUNE: 3.38 (-1.18), FB: 105.97 (+1.93), MRK: 53.94 (+0.24), STZ: 138.49 (+3.23), ILMN: 173.30 (+3.19), AAPL: 114.29 (+0.11)
Merck continuing study of cholesterol drug in new class
By LINDA A. JOHNSON - AP - Fri Nov 13, 1:16PM CST
TRENTON, N.J. (AP) — Merck & Co. said Friday that it will continue a huge patient study of an experimental cholesterol medicine, the last one standing in a once-promising class of drugs being developed to prevent heart attacks, after an independent monitoring committee recommended the study continue.
PFE: 33.25 (+0.09), MRK: 53.94 (+0.24), AMGN: 158.89 (+4.39), LLY: 81.72 (+0.49), REGN: 571.60 (+13.22)
Gilead's (GILD) HCV Drug Harvoni's Label Expanded in U.S.
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 1:15PM CST
Gilead Sciences, Inc. (GILD) announced a label expansion for its hepatitis C virus infection drug, Harvoni, in the U.S.
GILD: 104.68 (+0.87), MRK: 53.94 (+0.24), ABBV: 60.77 (+0.76), BXLT: 34.14 (-0.34)
Immune Design Posts Narrower-Than-Expected Loss for Q3
Zacks Equity Research - Zacks Investment Research - Fri Nov 13, 9:35AM CST
Immune Design's (IMDZ) Q3 loss was narrower than expected.
IMDZ: 18.60 (-0.15), MRK: 53.94 (+0.24), CORT: 4.79 (unch), SNY: 43.79 (+0.67)
Hepatitis C Treatment in 2016: Will Gilead Sciences or AbbVie Win?
Motley Fool Staff - Motley Fool - Fri Nov 13, 7:41AM CST
Gilead Sciences is a favorite healthcare stock for numerous Fools, and it's no surprise why. The recent stumble of AbbVie in its hepatitis C efforts has boosted the share price of Gilead, which has two key treatments that fight the illness. ...
GILD: 104.68 (+0.87), MRK: 53.94 (+0.24), ABBV: 60.77 (+0.76), BMY: 66.02 (+1.00)
